DESTINY-PanTumor02
Enhertu shrank tumours across many HER2-positive cancers, with endometrial cancer among the best responders, leading to the first tumour-agnostic HER2 approval.
Endometrial cohort ORR 57.5% overall and 84.6% in IHC 3+; cervical cohort ORR 50% (75% in IHC 3+) (JCO 2024). FDA accelerated approval April 2024 for HER2 IHC 3+ solid tumours with no satisfactory alternative. HER2 testing is now recommended in serous endometrial carcinoma.
- 57.5 vs 84.6 out of 100 had their tumour shrink with T-DXd (all HER2 IHC 2+/3+) compared with T-DXd (IHC 3+ only); 27.1 fewer per 100.
- On this measure the first group did worse, not better.
- 50 out of 100 people had their tumour shrink with T-DXd (all).
- There was no comparison group, so this number cannot tell you how much of the effect is due to the treatment.
- A response rate counts how many people had their tumours shrink by a set amount; shrinking is encouraging but does not by itself show that people live longer or feel better.
- These results apply to the people the trial enrolled: HER2-expressing (IHC 2+/3+) solid tumours after ≥1 line, seven cohorts including endometrial and cervical: trastuzumab deruxtecan. People in a different situation may not see the same effect.
- The trial selected people by a biomarker (HER2); the result should not be assumed for people whose cancer does not have it.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
267 participants enrolled.
Pages like this
not linked directly; found by shared links- TrialDESTINY-CRC02
Shares Tumour-agnostic (tissue-agnostic) approval, Trastuzumab deruxtecan, HER2.
- PersonBob T. Li
Shares Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC).
- ProductTrastuzumab duocarmazine
Shares Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC).
- TermEndometrial cancer molecular classes (POLEmut, MMRd, p53abn, NSMP)
Shares HER2 ADCs as standard for HER2-positive serous endometrial cancer, Endometrial cancer, HER2.
- InstitutionStephenson Cancer Center, OU Health
Shares Endometrial cancer, Cervical cancer, Antibody-drug conjugate (ADC).
- IdeaContinuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PersonNoboru Yamamoto
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PersonToshihiko Doi
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).